ORIONISBIO
LIVE

Serial Number

98338329

Owner

Orionis Biosciences Inc.

Attorney

Rachelle A. Dubow, Esq.

Filing Date

Jan 2, 2024

Add to watchlist:

No watchlists yet
View on USPTO

ORIONISBIO Trademark

Serial Number: 98338329

ORIONISBIO is a trademark filed by Orionis Biosciences Inc. on January 2, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Orionis Biosciences Inc. (8 trademarks)

Waltham, MA 02451

Entity Type: 03

Trademark Details

Filing Date

January 2, 2024

Registration Date

Not Registered

Published for Opposition

September 3, 2024

Goods & Services

Pharmaceutical products, serums and preparations for the treatment of cancer, auto immune disorders, metabolic disorders, neurological disorders, neuromuscular disorder; Pharmaceutical preparations, namely, cytokine inhibitory drugs; Therapeutic pharmaceutical and diagnostic preparations, namely, antibodies, cytokines, antigens, enzymes, immunoconjugates for treatment of cancer, immunological conditions, metabolic disorders; Biochemical and small molecule preparations for medical purposes for use in the treatment of cancer, auto immune diseases, metabolic diseases, neurological diseases, neuromuscular diseases

Development of new technology for others in the field of biotechnology; Scientific research and laboratory research services in the medical, bacteriological and biotechnical fields; Biotechnical research; Technical consultation and research in the field of biotechnological research; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Research and development of pharmaceuticals for others; Scientific and medical research in the fields of oncology, immunology and immune-oncology, inflammation, immune-mediated diseases, protein homeostasis, epigenetics and protein metabolism

Diagnostic, biological and chemical reagents for scientific and research use; Pharmaceutical intermediates for use in the further manufacture of pharmaceuticals; Active chemical or biological ingredients for use in the manufacture of pharmaceuticals for treating cancer, auto immune diseases, metabolic diseases, neurological diseases, neuromuscular diseases; Cytokines, namely, reagents for scientific and research use

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 21, 2026 EXRA
SOU EXTENSION 3 GRANTED
Apr 20, 2026 EX3G
SOU EXTENSION 3 FILED
Apr 20, 2026 EXT3
SOU TEAS EXTENSION RECEIVED
Apr 20, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 27, 2025 EXRA
SOU EXTENSION 2 GRANTED
Oct 24, 2025 EX2G
SOU EXTENSION 2 FILED
Oct 24, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Oct 24, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 11, 2025 EXRA
SOU EXTENSION 1 GRANTED
Apr 11, 2025 EX1G
SOU EXTENSION 1 FILED
Apr 11, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 10, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 29, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 3, 2024 NPUB
PUBLISHED FOR OPPOSITION
Sep 3, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 14, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 30, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 30, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 30, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 30, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 30, 2024 CNEA
ASSIGNED TO EXAMINER
Jul 30, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 16, 2024 NWOS
NEW APPLICATION ENTERED
Jan 2, 2024 NWAP